What malaria prophylaxis and treatment options are safe for a patient with glucose‑6‑phosphate dehydrogenase (G6PD) deficiency?

G6PD Deficiency and Malaria: Safe Treatment and Prophylaxis Options

For patients with G6PD deficiency, chloroquine and artemisinin-based combinations (artemether-lumefantrine, dihydroartemisinin-piperaquine, artesunate-atovoaquone-proguanil) are safe for both prophylaxis and treatment of acute malaria, while primaquine and tafenoquine require either dose adjustment or complete avoidance depending on deficiency severity. 1

Acute Malaria Treatment (Safe Options)

For P. falciparum (Uncomplicated):

• First-line choices: Artemether-lumefantrine (AL), dihydroartemisinin-piperaquine (DHA-PPQ), or artesunate-atovoaquone-proguanil (A-P) are all safe regardless of G6PD status 1
• These artemisinin-based combinations do not cause hemolysis in G6PD-deficient patients

For P. vivax/P. ovale (Uncomplicated):

• Chloroquine remains the preferred first-line agent for the acute blood-stage infection (4 tablets/1000mg initially, then 2 tablets/500mg at 6,24, and 48 hours) 1
• Alternative: DHA-PPQ or AL if chloroquine resistance suspected 1
• Hydroxychloroquine can substitute for chloroquine with better tolerability for prolonged use 2

For Severe/Complicated Malaria (Any Species):

• IV artesunate is the first-line treatment and is safe in G6PD deficiency (2.4 mg/kg at 0,12, 24h, then daily) 1
• Alternative: IV quinine (though watch for hypoglycemia and QT prolongation) 1

Radical Cure for P. vivax/P. ovale (The Critical Issue)

This is where G6PD status becomes crucial, as hypnozoite eradication requires 8-aminoquinolines:

G6PD Testing Requirements:

• Quantitative G6PD testing is mandatory before prescribing primaquine or tafenoquine 1, 3
• For females, qualitative tests are insufficient—quantitative assays are essential to distinguish deficient (<30%), intermediate (30-70%), and normal (>70%) activity 3
• Timing: G6PD activity remains stable throughout P. vivax infection, so testing can be done on Day 1 rather than waiting until Day 14, allowing earlier radical treatment 4

Based on G6PD Activity Level:

Normal Activity (>70%):

• Primaquine: 30mg base daily for 14 days 1
• Tafenoquine: Single 300mg dose (only if >70% activity) 1, 3

Intermediate Activity (30-70%, typically heterozygous females):

• Modified primaquine regimen: 0.75 mg/kg weekly for 8 weeks with close monitoring for hemolysis 1
• This applies specifically to non-Mediterranean variants (A-) 1
• Tafenoquine is contraindicated 3

Deficient Activity (<30%):

• Mediterranean variant (B-): Primaquine is absolutely contraindicated due to very high risk of severe hemolysis 1
• African variant (A-): Has mild deficiency and relative resistance to severe primaquine-induced hemolysis; weekly dosing may be considered with extreme caution 1
• Alternative approach: Chloroquine or hydroxychloroquine suppressive therapy without radical cure 2

Severe Deficiency (<10%):

• Primaquine and tafenoquine are absolutely contraindicated 1, 3
• Rely on suppressive therapy with chloroquine/hydroxychloroquine alone

Prophylaxis Options

Safe for All G6PD Status:

• Chloroquine 300mg base weekly (plus proguanil 200mg daily in areas of limited chloroquine resistance) 5
• Doxycycline 100mg daily 5
• Mefloquine 250mg weekly (though avoid if neuropsychiatric history) 5
• Atovaquone-proguanil daily

Contraindicated:

• Tafenoquine for prophylaxis requires >70% G6PD activity 3
• Primaquine for prophylaxis should be avoided in deficiency

Critical Pitfalls to Avoid

1. Do not use qualitative G6PD tests alone in females—they miss intermediate deficiency states that still carry hemolysis risk 3

2. Do not assume all G6PD deficiency is the same—Mediterranean variants have much higher hemolysis risk than African variants 1

3. Do not delay G6PD testing until Day 14—activity is stable from Day 1, and early testing prevents loss to follow-up (26.5% in one study) 4

4. Do not prescribe tafenoquine without quantitative G6PD confirmation of >70% activity—intermediate activity is a contraindication 3

5. In pregnancy with G6PD deficiency: Use chloroquine or hydroxychloroquine for suppression; defer radical cure until after delivery and breastfeeding when infant G6PD status can be determined 2

6. Post-artesunate delayed hemolysis (PADH) can occur even in G6PD-normal patients after IV artesunate for severe malaria—monitor hemoglobin for 4 weeks 1

The evidence strongly supports that with proper G6PD quantitative testing, safe malaria treatment is achievable in deficient patients using artemisinin combinations and chloroquine for acute disease, with carefully adjusted or deferred radical cure regimens based on deficiency severity and variant type.